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PXPEDITED REVIEW
ncomplete Neointimal
overage of Sirolimus-Eluting Stents
ngioscopic Findings
un-ichi Kotani, MD, FACC,* Masaki Awata, MD,* Shinsuke Nanto, MD,*
asaaki Uematsu, MD, FACC,* Fusako Oshima, MD,* Hitoshi Minamiguchi, MD,*
ary S. Mintz, MD, FACC,† Seiki Nagata, MD*
magasaki, Japan; and New York, New York
OBJECTIVES The goal of this study was to use angioscopy to investigate the amount of neointimal coverage
after sirolimus-eluting stent (SES) implantation.
BACKGROUND Sirolimus-eluting stents reduce intimal hyperplasia.
METHODS We used angioscopy to evaluate 37 consecutive stented coronary artery lesions (15 SES and
22 bare-metal stents [BMS]) in 25 patients (18 men, 7 women) at 3 to 6 months after stent
implantation. Angioscopic evaluation focused on: 1) neointimal coverage of stent struts, and
2) the existence of thrombi. The degree of neointimal coverage was classified as grade 0 when
there was no neointimal coverage (similar to immediately after the implantation); grade 1
when stent struts bulged into the lumen, but were covered and still translucently visible; grade
2 when stent struts were visible but not clearly seen (not translucent); and grade 3 when stent
struts were not visible because they were embedded in the neointima.
RESULTS Thrombi were identified in eight stented segments, tended to be more common with SES
(p  0.14), but were not seen on angiography. Three of the 15 SES (20%) had grade 0
neointimal coverage, and only 2 SES (13.3%) had complete coverage (grades 2/3). In contrast,
all 22 BMS showed complete intimal coverage (grades 2/3). Thrombi were more common in
stents with incomplete neointimal coverage (p  0.09).
CONCLUSIONS The SES had incomplete neointimal coverage three to six months after implantation, and this
was associated with subclinical thrombus formation. (J Am Coll Cardiol 2006;47:2108–11)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.11.092© 2006 by the American College of Cardiology Foundation
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iirolimus-eluting stents (SES) have remarkably reduced
estenosis by inhibiting neointimal proliferation compared
ith bare-metal stents (BMS) (1,2). However, similar to
ascular brachytherapy (VBT), SES may have an increased
See page 2112
ate of late thrombosis (3–8). One pathologic study has
elated late thrombosis to incomplete neointimal coverage
7). Angioscopy is a robust tool capable of visualizing both
tent strut neointimal coverage as well as intracoronary
hrombus formation in vivo (9–11). We used angioscopy to
nvestigate the amount of neointimal coverage and throm-
us formation after SES implantation compared with BMS.
ETHODS
atient population. We evaluated 37 consecutive stented
oronary artery lesions in 25 patients (18 men and 7 women,
ean age 65 years, range 54 to 78 years) who agreed to
ollow-up angiography and angioscopy 3 to 6 months after
From the *Cardiovascular Division, Kansai Rosai Hospital, Amagasaki, Japan, and
he †Cardiovascular Research Foundation, New York, New York. This research was
artly supported by the Japan Labour, Health, and Welfare Organization.t
Manuscript received July 31, 2005; revised manuscript received September 19,
005, accepted November 1, 2005.tent implantation. Stents were implanted using standard
echniques. We compared the angioscopic findings of
5 SES-treated lesions (Cypher, Cordis, Miami Lakes,
lorida) with 22 BMS (Bx Velocity, Cordis, n 5; Driver,
edtronic, Galway, Ireland, n  4; Zeta, Guidant, India-
apolis, Indiana, n  8; Express 2, Boston Scientific,
atick, Massachusetts, n  4; and Duraflex, Goodman,
alway, Ireland, n  1). Because SES did not become
vailable until August 2004, all patients treated before this
ate received BMS, and all patients treated after this date
eceived SES. The Medical Ethics Committee at Kansai
osai Hospital approved this study, and patients gave
ritten informed consent. All patients received dual-
ntiplatelet therapy (aspirin 100 mg and ticlopidine 200 mg)
fter the procedure; at the time of this study, clopidogrel
as not approved in Japan.
ngioscopic procedures and evaluation. At follow-up, all
tents were assessed with an 0.014-inch guidewire-
ompatible 4.5-F rapid-exchange coronary angioscope
Vecmova, Clinical Supply Corp., Gifu, Japan): BMS 
31  48 days versus SES  115  48 days (p  NS). The
ystem and its use have been described elsewhere (9).
riefly, all patients were given a bolus of 5,000 IU heparin
ntravenously before angiography and angioscopy. The op-
ical fiber was placed at the distal segment of the coronary
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May 16, 2006:2108–11 Angioscopic Evaluation of SESrtery and slowly pulled back from the distal edge of the
tent to the proximal edge under angioscopic and angio-
raphic guidance.
Angioscopic evaluation focused on: 1) the degree of stent
trut neointimal coverage, and 2) the existence of red or
hite thrombi. Neointimal coverage was classified into four
rades (Fig. 1). Grade 0 was defined as stent struts that were
ully visible, similar to immediately after implantation.
rade 1 was defined as stent struts that bulged into the
umen and, although covered, were still transparently visible.
rade 2 was defined as stent struts that were visible, but not
learly seen (i.e., they were translucent). Grade 3 was
efined as stent struts that were not visible by angioscopy
i.e., they were embedded in the neointima). Struts that
rossed side branches were excluded from grading because
hey all showed grade 0 coverage. (This grading system
volved from one previously reported [11].) Taken together,
rade 0/1 indicated incomplete neointimal coverage,
Abbreviations and Acronyms
BMS  bare-metal stent
IVUS  intravascular ultrasound
SES  sirolimus-eluting stent
VBT  vascular brachytherapyigure 1. Angioscopic images show the grading for neointimal stent strut co
ompared with sirolimus-eluting stents (p  0.0001).hereas grade 2/3 indicated complete coverage. In three
ES and three BMS, neointimal coverage was heteroge-
eous; in these six cases the dominant pattern was tabulated.
ngiographic assessment. Coronary angiography was per-
ormed in 10 regular projections, and quantitative coronary
ngiography performed using the CASS system (Pie Med-
cal Imaging B.V., Maastricht, the Netherlands) with the
worst view” used to assess the severity of the stenosis (12).
tatistical analysis. Statistical analysis was performed us-
ng StatView 5.0 (SAS Institute, Cary, North Carolina).
ontinuous variables were expressed as mean  1 SD and
nalyzed by unpaired Student t test or analysis of variance.
ategorical variables were expressed as frequencies and
nalyzed by chi-square statistics or Fisher exact test (for 2
comparisons); p  0.05 was considered significant.
ESULTS
atient and lesion characteristics. There were no signif-
cant differences in demographics (age, gender, past history,
nd coronary risk factors) between patients receiving BMS
ersus SES (data not shown). Lesion characteristics were
lso similar between the two groups (Table 1). There was no
ifference in diabetes frequency between BMS (n  15;
8.2%) and SES (n  11; 73.3%) (p  1.0). There was noverage. Neointimal coverage was more complete with bare-metal stents
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Angioscopic Evaluation of SES May 16, 2006:2108–11ignificant difference in duration of dual-antiplatelet therapy
etween BMS (85  58 days) versus SES (115  47 days,
 0.1).
ngiographic assessment. There were no differences in
uantitative coronary angiography findings between BMS
nd SES groups before and immediately after stent implan-
ation (Table 2). At follow-up, the SES group had a larger
inimal lumen diameter than the BMS group (Table 2).
herefore, late loss was significantly higher in BMS than in
ES group (0.8  0.6 mm in BMS vs. 0.2  0.4 mm in
ES, p  0.0013).
ngioscopic findings. Thrombi were identified in eight
tented segments. All were mural thrombi, none were
cclusive, and none were detectable by angiography. Five
ed thrombi were detected in 15 SES (33%), whereas 2 red
hrombi and 1 white thrombus were detected in 22 BMS
14%), p  0.14.
Angioscopic grades of neointimal coverage were mark-
dly different between BMS and SES (p 0.0001) (Fig. 1).
hree of 15 SES (20%) had grade 0 coverage, and only 2
13.3%) had complete coverage (grades 2/3). In contrast, all
2 BMS had complete intimal coverage (grades 2/3). The
rade of neointimal coverage was related to the duration of
ollow-up in BMS (p  0.058), but not in SES (p  1.0).
The relationship between the degree of neointimal cov-
rage and the presence of thrombi is shown in Table 3. In
he entire cohort of 37 stented lesions, there was a tendency
or thrombi to be correlated with incomplete neointimal
overage (p  0.09 by Fisher exact test).
able 1. Lesion Characteristics
BMS SES p Value
22 15
essels (LAD/LCX/RCA) 7/4/11 6/2/7 0.9
ocation (proximal/middle/distal) 7/15/0 5/8/2 0.2
nfarct related artery (n) 11 4 1.0
tent diameter (mm) 3.2  0.3 3.0  0.4 0.2
tent length (mm) 22.1  4.8 22.7  8.8 0.7
MS  bare-metal stent; LAD  left anterior descending artery; LCX  left
ircumflex artery; RCA  right coronary artery; SES  sirolimus-eluting stent.
able 2. Quantitative Coronary Angiography Findings
BMS DES p Value
re-procedure
Reference vessel diameter (mm) 2.8  0.4 2.7  0.5 0.7
Lesion length (mm) 16.7  6.1 16.6  8.1 1.0
Minimal lumen diameter (mm) 0.8  0.6 0.6  0.5 0.2
Diameter stenosis (%) 73.7  12.0 77.5  18.1 0.4
ost-stent implantation
Minimal lumen diameter (mm) 2.6  0.3 2.6  0.5 1.0
Diameter stenosis (%) 15.2  5.9 18.3  5.4 0.1
ollow-up
Minimal lumen diameter (mm) 1.8  0.6 2.3  0.7 0.0255
Diameter stenosis (%) 32.2  20.4 22.5  17.7 0.1wMS  bare-metal stent; DES  drug-eluting stent.ISCUSSION
he present study showed significant differences between
eointimal coverage of BMS versus SES three to six months
fter implantation. All BMS had complete neointimal
overage, whereas neointima covering of SES struts was
ore lucent and less complete. Furthermore, incomplete
eointimal coverage was associated with thrombus forma-
ion that tended to be more common in SES than in BMS.
Intravascular ultrasound (IVUS) studies showed that
n-stent restenosis was secondary to neointimal hyperplasia.
arlier angioscopic studies showed that complete neointi-
al coverage was the rule in BMS (9–11). The IVUS
tudies also showed that drug-eluting stents reduced in-
tent restenosis by inhibiting neointimal hyperplasia. Fur-
hermore, one previous IVUS study showed that nonpoly-
eric paclitaxel-eluting stents not only inhibited intimal
yperplasia, but also increased the neointimal-free length of
he stents; the length of stent that was free of IVUS-
etectable intimal hyperplasia measured 3.2  4.8 mm in
lacebo stents, 6.1  5.6 mm in low-dose stents, and 8.7 
.1 mm in high-dose stents (p  0.0029) (13). The current
tudy extended these observations by showing that SES not
nly suppressed intimal hyperplasia, but also left a signifi-
ant portion of the stent struts fully exposed and uncovered,
imilar to immediately after implantation.
In the current study, the lack of neointimal strut coverage
as associated with thrombus formation. One previous
athological study reported that impaired healing (i.e.,
ailure to form a complete neointimal layer over the stent
truts) extended the window during which stents were prone
o thrombosis (7), and VBT also inhibited neointimal
rowth. In patients treated with VBT, the lack of re-
ndothelialization and late thrombosis were related, espe-
ially in the setting of new stent implantation (7,14). On the
ther hand, prolonged intensive antiplatelet therapy or
educed restenting when treating in-stent restenosis with
BT decreased the late stent thrombosis rate (8).
One earlier serial angioscopic study showed that intimal
overage of BMS proceeded gradually with subsequent
eointimal remodeling (shrinkage) up to two years (11).
imilarly, in the current analysis the grade of neointimal
overage in BMS was related to the time from implantation
o angioscopic follow-up even though all angioscopic stud-
es were performed within six months. A recent case report
n the pathology of SES-treated lesions showed that endo-
helial coverage was 80% complete after 16 months (15).
n the current study, neointimal coverage was unrelated to
he time from DES implantation to angioscopic follow-up
able 3. Relationship Between Intimal Coverage and Thrombus
Incomplete
(Grade 0/1)
Complete
(Grade 2/3)
hrombus present 5 3
hrombus absent 8 21hen all follow-up studies were performed within six
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May 16, 2006:2108–11 Angioscopic Evaluation of SESonths; therefore, the time course for neointimal coverage
s more prolonged than with BMS. On the other hand, late
atch-up after VBT has been well shown, and SES may
ave a similar late catch-up potential (16,17). Longer-term
erial angioscopic observations will be necessary to clarify
he chronological findings; however, these data may be
ifficult to obtain.
tudy limitations. The structural designs of the stents used
n our study were not identical between the BMS and the
ES groups. Therefore, we could not exclude effects of
echanical designs on the angioscopic findings. This was
ot a serial study; therefore, we could not compare the
hronological course of neointimal coverage between BMS
nd SES. All angioscopic studies were performed within six
onths after implantation, and the interval from implanta-
ion to follow-up ranged from three to six months. Longer-
erm study (beyond 12 months) will be required to address
he issue of late, late thrombosis. Finally, this study only
nvestigated neointimal morphology; local endothelial func-
ion remained unclear; and grade 1 with a functional
eointima might be as good as grade 2 or 3 coverage.
onclusions. Angioscopic findings of neointimal coverage
ithin six months after implantation were quite different
etween BMS and SES. The SES had incomplete neoin-
imal coverage three to six months after implantation, and
his was associated with subclinical thrombus formation.
his supports prolonged dual-antiplatelet therapy for pa-
ients treated with SES.
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